Mechanisms controlling sensitivity to platinum complexes: Role of p53 and DNA mismatch repair

Current Cancer Drug Targets

Volumn 3, Issue 1, 2003, Pages 21-29

  Manic, S ^c   Gatti, L ^c   Carenini, N ^c   Fumagalli, G ^a   Zunino, F ^c   Perego, P ^b  

^a UNIVERSITY OF VERONA   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

BBR 3464; CARBOPLATIN; CISPLATIN; CYTOTOXIC AGENT; OXALIPLATIN; PLATINUM COMPLEX; PROTEIN P53; SATRAPLATIN; TRANS AMMINEDICHLORO(CYCLOHEXYLAMINE)DIHYDROXOPLATINUM;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL TRIAL; CYTOTOXICITY; DRUG EFFECT; DRUG MECHANISM; DRUG POTENCY; DRUG RESISTANCE; DRUG SENSITIVITY; DRUG STRUCTURE; EXCISION REPAIR; HUMAN; MISMATCH REPAIR; MOLECULAR RECOGNITION; STRUCTURE ACTIVITY RELATION; TUMOR RESISTANCE;

ANTINEOPLASTIC AGENTS; BASE PAIR MISMATCH; CLINICAL TRIALS; DNA ADDUCTS; DNA DAMAGE; DNA REPAIR; DRUG RESISTANCE, NEOPLASM; HUMANS; NEOPLASMS; ORGANOPLATINUM COMPOUNDS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 12244250732     PISSN: 15680096     EISSN: None     Source Type: Journal    
DOI: 10.2174/1568009033333727     Document Type: Article

References (77)

1. Judson, I.; Kelland, L. R. New Development and Approaches in the Platinum Area. Drugs 2000, 59, 29-36.
2. Rosenberg, R. In Cisplatin, Current Status and New Developments; Prestayko, A.W.; Crooke, S.T.; Lanter, S.K.; Academic Press: NJ, 1987, pp. 11.
3. Giaccone, G. Clinical Perspectives on Platinum Resistance. Drugs 2000, 59, 37-38.
4. Takahare, P. M.; Rosenzweig, A. C.; Frederick, C. A.; Lippard, S. J. Crystal Structure of Double-Stranded DNA Containing the Major Adduct of the Anticancer Drug Cisplatin. Nature 1995, 377, 649-652.
5. Eastman, A. Reevaluation of Interaction of Cis- Dichloro(Ethylenediamine)Platinum(II) with DNA. Biochemistry 1986, 25, 3912-3915.
6. Hayes, J. J.; Scovell, W. M. Cis- Diamminedichloroplatinum(II) Modified Chromatin and Nucleosomal Core Particle Probed with DNase I. Biochim. Biophys. Acta 1991, 1088, 413-418.
7. Kartalou, M.; Essigmann, J. M. Mechanisms of Resistance to Cisplatin. Mutat. Res. 2001, 478, 23-43.
8. Gately, D. P.; Howell, S. B. Cellular Accumulation of the Anticancer Agent Cisplatin: a Review. Br. J. Cancer 1993, 67, 1171-1176.
9. Mann, S. C.; Andrews, P. A.; Howell, S. B. Short-Term Cisdiamminedichloroplatinum(II) Accumulation in Sensitive and Resistant Human Ovarian Carcinoma Cells. Cancer Chemother. Pharmacol. 1990, 25, 236-240.
10. Kondo, Y.; Kuo, S. M.; Watkins, S. C.; Lazo, J. S. Metallothionein Localization and Cisplatin Resistance in Human Hormone-Independent Prostatic Tumor Cell Lines. Cancer Res. 1995, 55, 474-477.
11. Mistry, P.; Kelland, L. R.; Abel, G.; Sidhar, S.; Harrap, K. R. the Relationships Between Glutathione, Glutathione- S-Transferase and Cytotocity of Platinum Drugs and Melphalan in Eight Human Ovarian Carcinoma Cell Lines. Br. J. Cancer 1991, 64, 215-220.
12. Eastman, A.; Schulte, N. Enhanced DNA Repair as a Mechanism of Resistance to Cis-Diamminedichloroplatinum(II). Biochemistry 1988, 27, 4730-4734.
13. Lage, H.; Dietel, M. Involvement of the DNA Mismatch Repair System in Antineoplastic Drug Resistance. J. Cancer Res. Clin. Oncol. 1999, 125, 156-165.
14. Kool, M.; De Haas, M.; Scheffer, G. L.; Scheper, R. J.; Van Eijk, M. J.; Juijn, J. A.; Baas, F.; Borst, P. Analysis of Expression of CMOAT (MRP2), MRP3, MRP4, and MRP5, Homologues of the Multidrug Resistance-Associated Protein Gene (MRP1), in Human Cancer Cell Lines. Cancer Res. 1997, 57, 3537-3547.
15. Ishikawa, T.; Wright, C. D.; Ishizuka, H. Gs-X Pump is Functionally Overexpressed in Cis-Diamminedichloroplatinum (II)-Resistant Human Leukemia H-60 Cells and Down-Regulated by Cell Differentiation. J. Biol. Chem. 1994, 269, 29085-29093.
16. Komatsu, M.; Sumizawa, T.; Mutoh, M.; Chen, Z. S.; Terada, K., Furukawa, T.; Yang, X. L.; Gao, H.; Miura, N.; Sugiyama, T.; Akiyama, S. Copper-Transporting P-Type Adenosine Triphosphatase (ATP7b) is Associated with Cisplatin Resistance. Cancer Res. 2000, 60, 1312-1316.
17. Chaney, S. G.; Sancar, A. DNA Repair: Enzymatic Mechanisms and Relevance to Drug Response. J. Natl. Cancer Inst. 1996, 88, 1346-1360.
18. Schmidt, W.; Chaney, S. G. Role of Carrier Ligand in Platinum Resistance of Human Carcinoma Cell Lines. Cancer Res. 1993, 53, 799-805.
19. Vaisman, A.; Varchenko, M.; Umar, A.; Kunkel, T. A.; Risinger, J. I.; Barrett, J. C.; Hamilton, T. C.; Chaney, S. G. The Role of HMLH1, HMSH3, and HMSH6 Defects in Cisplatin and Oxaliplatin Resistance: Correlation with Replicative Bypass of Platinum-DNA Adducts. Cancer Res. 1998, 58, 3579-3585.
20. Zunino, F.; Perego, P.; Pilotti, S.; Pratesi, G.; Supino, R.; Arcamone, F. Role of Apoptotic Response in Cellular Resistance to Cytotoxic Agents. Pharmacol. Ther. 1997, 76, 177-185.
21. Perego, P.; Righetti, S. C.; Supino, R.; Delia, D.; Caserini, C.; Carenini, N.; Bedognè, B.; Broome, E.; Krajewski, S.; Reed, J. C.; Zunino, F. Role of Apoptosis and Apoptosis-Related Proteins in the Cisplatin-Resistant Phenotype of Human Tumor Cell Lines. Apoptosis 1997, 2, 540-548.
22. Fink, D.; Nebel, S.; Aebi, S.; Zheng, H.; Cenni, B.; Nehme, A.; Christen, R.; Howell, S. The Role of DNA Mismatch Repair in Platinum Drug Resistance. Cancer Res. 1996, 56, 4881-4886.
23. Kelland, L.R. New Platinum Drugs. In Platinum-Based Drugs In Cancer Therapy; Kelland, L. R.; Farrell, N.; Humana Press Inc.: Totowa, NJ, 2000, pp. 299-319.
24. Farrell, N. Polynuclear Charged Platinum Compounds as a New Class of Anticancer Agents. In Platinum-Based Drugs in Cancer Therapy; Kelland, L. R.; Farrell, N.; Humana Press Inc.: Totowa, NJ, 2000, pp. 321-338.
25. Laadem, A.; Cvitkovic, E. Oxaliplatin: A First Dach- Platinum in Oncology. Bull. Cancer 2001, S9-13.
26. Woynarowski, J. M.; Faivre, S.; Herzig, M. C. S.; Arnett, B.; Chapman, W. G.; Trevino, A. V.; Raaymond, E.; Chaney, S. G.; Vaisman, A.; Varchenco, M.; Juniewich, P. E. Oxaliplatin-Induced Damage of Cellular DNA. Mol. Pharmacol. 2000, 58, 920-927.
27. Gonzalez, V. M.; Fuertes, M. G.; Aloonso, C; Perez, J. M. Is Cisplatin-Induced Cell Death Always Produced by Apoptosis? Mol. Pharmacol. 2001, 59, 657-663.
28. Manzotti, C.; Pratesi, G.; Menta, E.; Di Domenico, R.; Cavalletti, E.; Fiebig, H. H.; Kelland, L. R.; Farrell, N.; Polizzi, D.; Supino, R.; Pezzoni, G.; Zunino, F. BBR3464: a Novel Platinum Complex Exhibiting a Preclinical Profile of Antitumor Efficacy Different from Cisplatin. Clin. Cancer Res. 2000, 6, 2626-2634.
29. Pratesi, G.; Perego, P.; Polizzi, D.; Righetti, S. C.; Supino, R.; Caserini, C.; Manzotti, C.; Giuliani, F. C.; Pezzoni, G.; Tognella, S.; Spinelli, S.; Farrell, N.; Zunino, F. A Novel Charged Trinuclear Platinum Complex Effective Against Cisplatin-Resistant Tumors: Hypersensitivity of p53 -Mutant Human Tumor Xenografts. Br. J. Cancer 1999, 80, 1912-1919.
30. Perego, P.; Caserini, C.; Gatti, L.; Carenini, N.; Romanelli, S.; Supino, R.; Colangelo, D.; Viano, I.; Leone, R.; Spinelli, S.; Pezzoni, G.; Manzotti, C.; Farrell, N.; Zunino, F. A Novel Trinuclear Platinum Complex Overcome Cisplatin Resistance in an Osteosarcoma Cell System. Mol. Pharmacol. 1999, 55, 528-534.
31. Zehnulova, J.; Kasparkova, J.; Farrell, N.; Brabec, V. Conformation, Recognition by High Mobility Group Domain Proteins, and Nucleotide Excision Repair of DNA Intrastrand Cross-Links of Novel Antitumor Trinuclear Platinum Complex Bbr3464. J. Biol. Chem. 2001, 276, 22191-22199.
32. Lane, D. P. Cancer. p53, Guardian of the Genome. Nature 1992, 358, 16.
33. Gottlieb, T. M., Oren, M. p53 and Apoptosis. Semin. Cancer Biol. 1998, 8, 359-368.
34. Lozano, G.; Elledge, S. J. p53 Sends Nucleotides to Repair DNA. Nature 2000, 404, 42-49.
35. Miyashita, T.; Reed, J. C. Tumor Suppressor p53 is a Direct Transcriptional Activator of the Human Bax Gene. Cell 1995, 80, 293-299.
36. Vogelstein, B.; Lane, D.; Levine, A. J. Surfing the p53 Network. Nature 2000, 408, 307-310.
37. Tanaka, H.; Arakawa, H.; Yamaguchi, T.; Shiraishi, K.; Fukuda, S.; Matsui, K.; Takei, Y.; Nakamura, Y. A Ribonucleotide Reductase Gene Involved in a p53 -Dependent Cell-Cycle Checkpoint for DNA Damage. Nature 2000, 404, 42-49.
38. Perego, P.; Giarola, M.; Righetti, S. C.; Supino, R.; Caserini, C.; Delia, D.; Pierotti, M. A.; Miyashita, T.; Reed, J. C.; Zunino, F. Association Between Cisplatin Resistance and Mutation of p53 Gene and Reduced Bax Expression in Ovarian Carcinoma Cell System. Cancer Res. 1996, 56, 556-562.
39. Pestell, K. E.; Hobbs, S. M.; Titley, J. C.; Kelland, L. R.; Walton, M. I. Effect of p53 Status on Sensitivity to Platinum Complexes in a Human Ovarian Cancer Cell Line. Mol. Pharmacol. 2000, 57, 503-511.
40. Fan, S.; Smith, M. L.; Rivet, D. J.; Duba, D.; Zhan, Q.; Kohn, K. W.; Fornace, A. J.; O'connor, P. M. Disruption of p53 Function Sensitizes Breast Cancer Mcf-7 Cells to Cisplatin and Pentoxifylline. Cancer Res. 1995, 55, 1649-1654.
41. Lai, S. L.; Perng, R. P.; Hwang, J. p53 Gene Status Modulates the Chemosensitivity of Non-Small Cell Lung Cancer. J. Biomed. Sci. 2000, 7, 64-70.
42. Righetti, S. C.; Della Torre, G.; Pilotti, S.; Menard, S.; Ottone, F.; Colnaghi, M. I.; Pierotti, M. A.; Lavarino, C.; Cornarotti, M.; Oriana, S.; Bohm, S.; Bresciani, L.; Spatti, G.; Zunino, F. A Comparative Study of p53 Gene Mutations, Protein Accumulation, and Response to p53 Cisplatin-Based Chemotherapy in Advanced Ovarian Carcinoma. Cancer Res. 1996, 56, 689-693.
43. Lavarino, C.; Pilotti, S.; Oggionni, M.; Gatti, L.; Perego, P.; Bresciani, G.; Pierotti, M. A.; Scambia, G.; Ferrandina, G.; Fagotti, A.; Mangioni, C.; Lucchini, V.; Vecchione, F.; Bolis, G.; Scarfone, G.; Zunino, F. p53 Gene Status and Response to Platinum/Paclitaxel-Based Chemotherapy in Advanced Ovarian Carcinoma. J. Clin. Oncol. 2000, 18, 3936-3945.
44. Marin, M. C.; Jost, C. A.; Brooks, L. A.; Irwin, M. S.; O'nions, J.; Tidy, J. A.; James, N.; Mcgregor, J. M.; Harwood, C. A.; Yulug, I. G.; Vousden, K. H.; Allday, M. J.; Gusterson, B.; Ikawa, S.; Hinds, P. W.; Crook, T.; Kaelin, W. G. A Common Polymorphism Acts as an Intragenic Modifier of Mutant p53 Behavior. Nat. Genet. 2000, 25, 47-54.
45. Levrero, M.; De Laurenzi, V.; Costanzo, A.; Gong, J.; Wang, J. Y.; Melino, G. the p53 /p63/p73 Family of Transcription Factors: Overlapping and Distinct Functions. J. Cell. Sci. 2000, 113, 1661-1670.
46. Gong, J. G.; Costanzo, A.; Yang, H. Q.; Melino, G.; Kaelin, W. G. Jr; Levrero, M.; Wang, J. Y. The Tyrosine Kinase C-Abl Regulates p73 in Apoptotic Response to Cisplatin-Induced DNA Damage. Nature 1999, 399, 806-809.
47. Perego, P.; Caserini, C.; Gatti, L.; Carenini, N.; Romanelli, S.; Supino, R.; Colangelo, D.; Viano, I.; Leone, R.; Spinelli, S.; Pezzoni, G.; Manzotti, C.; Farrell, N.; Zunino, F. A Novel Trinuclear Platinum Complex Overcomes Cisplatin Resistance in an Osteosarcoma Cell System. Mol. Pharmacol. 1999, 55, 528-534.
48. Perego, P.; Romanelli, S.; Carenini, N.; Magnani, I.; Leone, R.; Bonetti, A.; Paolicchi, A.; Zunino, F. Ovarian Cancer Cisplatin-Resistant Cell Lines: Multiple Changes Including Collateral Sensitivity to Taxol. Ann. Oncol. 1998, 9, 423-430.
49. Lanzi, C.; Perego, P.; Supino, R.; Romanelli, S.; Pensa, T.; Carenini, N.; Viano, I.; Colangelo, D.; Leone, R.; Apostoli, P.; Cassinelli, G.; Gambetta, R. A.; Zunino, F. Decreased Drug Accumulation and Increased Tolerance to DNA Damage in Tumor Cells with a Low Level of Cisplatin Resistance. Biochem. Pharmacol. 1998, 55, 1247-1254.
50. Gayet, J.; Zhou, X. P.; Duval, A.; Rolland, S.; Hoang, J. M.; Cottu, P.; Hamelin, R. Extensive Characterization of Genetic Alterations in a Series of Human Colorectal Cancer Cell Lines. Oncogene 2001, 20, 5025-5032.
51. Tang, W.; Willers, H.; Powell, S.N. p53 Directly Enhances Rejoining of DNA Double-Strand Breaks with Cohesive Ends in Gamma-Irradiated Mouse Fibroblasts. Cancer Res. 1999, 59, 2562-2565.
52. Lee, S.; Elenbaas, B.; Levine, A.; Griffith, J. p53 and Its 14 Kda C-Terminal Domain Recognize Primary DNA Damage in the Form of Insertion/Deletion Mismatches. Cell 1995, 81, 1013-1020.
53. Reed, M.; Woelker, B.; Wang, P.; Wang, Y.; Anderson, M. E.; Tegtmeyer, P. The C-Terminal Domain of p53 Recognizes DNA Damaged by Ionizing Radiation. Proc. Natl. Acad. Sci USA 1995, 92, 9455-9459.
54. Wetzel, C. C.; Berberich, S. J. DNA Binding Activities of p53 Protein Following Cisplatin Damage of Ovarian Cells. Oncol. Res. 1998, 10, 151-161.
55. Wetzel, C. C.; Berberich, S. J. p53 Binds to Cisplatin- Damaged DNA. Biochim. Biophys. Acta 2001, 1517, 392-397.
56. + Tumor Cells. Cell 1993, 75, 1227-1236.
57. Fishel, R.; Kolodner, R. D. Identification of Mismatch Repair Genes and their Role in the Development of Cancer. Curr. Opin. Genet. Dev. 1995, 5, 382-395.
58. Aebi, S.; Kurdi-Haidar, B.; Gordon, R.; Cenni, B.; Zhen, H.; Fink, D.; Christen, R. D.; Boland, C. R.; Koi, M.; Fishel, R.; Howell, S. B. Loss of DNA Mismatch Repair in Acquired Resistance to Cisplatin. Cancer Res. 1996, 56, 3087-3090.
59. Anthoney, D. A.; Mcilwrath, A. J.; Gallagher, W. M.; Edlin, A. R.; Brown, R. Microsatellite Instability, Apoptosis, and Loss of p53 Function in Drug-Resistant Tumor Cells. Cancer Res. 1996, 56, 1374-1381.
60. Hoffmann, J. S.; Cazaux, C. DNA Synthesis, Mismatch Repair and Cancer. Int. J. Oncol. 1998, 12, 377-382.
61. Honma, M.; Momose, M.; Tanabe, H.; Sakamoto, H.; Yu, Y.; Little, J. B.; Sofuni, T.; Hayashi, M. Requirement of Wild-Type p53 Protein for Maintenance of Chromosomal Integrity. Mol. Carcinog. 2000, 28, 203-214.
62. Branch, P.; Masson, M.; Aquilina, G.; Bignami, M.; Karran, P. Spontaneous Development of Drug Resistance: Mismatch Repair and p53 Defects in Resistance to Cisplatin in Human Tumor Cells. Oncogene 2000, 19, 3138-3145.
63. Lin, X.; Ramamurthi, K.; Mishima, M.; Kondo, A.; Christen, R. D.; Howell, S. B. p53 Modulates the Effect of Loss of DNA Mismatch Repair on the Sensitivity of Human Colon Cancer Cells to the Cytotoxic and Mutagenic Effects of Cisplatin. Cancer Res. 2001, 61, 1508-1516.
64. Weeda, G.; Hoeijmakers, J. H.; Bootsma, D. Genes Controlling Nucleotide Excision Repair in Eukaryotic Cells. Bioessays 1993, 15, 249-258.
65. Boulikas, T. Xeroderma Pigmentosum and Molecular Cloning of DNA Repair Genes. Anticancer Res. 1996, 16, 693-708.
66. Huang, J. C.; Zamble, D. B.; Reardon, J.T.; Lippard, S. J.; Sancar, A. Hmg-Domain Proteins Specifically Inhibit the Repair of the Major DNA Adduct of the Anticancer Drug Cisplatin by Human Excision Nuclease. Proc. Natl. Acad. Sci. USA 1994, 91, 10394-10398.
67. Perego, P.; Zunino, F.; Carenini, N.; Giuliani, F.; Spinelli, S.; Howell, S. B. Sensitivity to Cisplatin and Platinum- Containing Compounds of Schizosaccharomyces Pombe Rad Mutants. Mol. Pharmacol. 1998, 54, 213-219.
68. Perego, P.; Jimenez, G. S.; Gatti, L.; Howell, S. B.; Zunino, F. Yeast Mutants as a Model System for Identification of Determinants of Chemosensitivity. Pharmacol. Rev. 2000, 52, 477-491.
69. Mu, D.; Hsu, D. S.; Sancar, A. Reaction Mechanism of Human DNA Repair Excision Nuclease. J. Biol. Chem. 1996, 271, 8285-8294.
70. Koberle, B.; Masters, J. R.; Hartley, J. A.; Wood, R. D. Defective Repair of Cisplatin-Induced DNA Damage Caused by Reduced Xpa Protein in Testicular Germ Cell Tumours. Curr. Biol. 1999, 9, 273-276.
71. Wang, X. W.; Yeh, H.; Schaeffer, L.; Roy, R.; Moncollin, V.; Egly, J. M.; Wang, Z.; Freidberg, E. C.; Evans, M. K.; Taffe, B. G.; Bohr, V. A.; Weeda, G.; Hoeijmakers, J. H. J.; Forrester, K.; Harris, C. C. p53 Modulation of TFIIH-Associated Nucleotide Excision Repair Activity. Nat. Genet. 1995, 10, 188-195.
72. Holford, J.; Sharp, S. Y.; Morrer, B. A.; Abrams, M.; Kelland, L. R. In vitro Circumvention of Cisplatin Resistance by the Novel Sterically Hindered Platinum Complex AMD473. Br. J. Cancer 1998, 77, 366-73.
73. Holford, J.; Beale, P. J.; Boxall, F. E.; Sharp, S. Y.; Kelland, L. R. Mechanisms of Drug Resistance to the Platinum Complex ZD0473 in Ovarian Cancer Cell Lines. Eur. J. Cancer 2000, 36, 1984-1990.
74. Kasparkova, J.; Pospisilova, S.; Brabec, V. Different Recognition of DNA Modified by Antitumor Cisplatin and its Clinically Ineffective Trans Isomer by Tumor Suppressor Protein p53. J. Biol. Chem. 2001, 276, 16064-16069.
75. Perez, M. J.; Fuertes, A. M.; Alons, C.; Ranninger, N. C. Current Status of the Development of Trans-Platinum Antitumor Drugs. Critical Reviews In Oncology/Hematology 2000, 35, 109-120.
76. 2(Amine)(Isopropilamine)]Compounds: Cytotoxic Activity and Apoptosis Induction in Ras-Transformed Cells. J. Med. Chem. 1999, 42, 4264-4268.
77. 3 by an Iminoether in Transplatin Makes and Antitumor Drug from an Inactive Compound. Mol. Pharmacol. 2000, 58, 1525-1535.